These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

294 related items for PubMed ID: 16005175

  • 1. The effects of RANK blockade and osteoclast depletion in a model of pure osteoblastic prostate cancer metastasis in bone.
    Whang PG, Schwarz EM, Gamradt SC, Dougall WC, Lieberman JR.
    J Orthop Res; 2005 Nov; 23(6):1475-83. PubMed ID: 16005175
    [Abstract] [Full Text] [Related]

  • 2. Soluble receptor activator of nuclear factor kappaB Fc diminishes prostate cancer progression in bone.
    Zhang J, Dai J, Yao Z, Lu Y, Dougall W, Keller ET.
    Cancer Res; 2003 Nov 15; 63(22):7883-90. PubMed ID: 14633717
    [Abstract] [Full Text] [Related]

  • 3. Osteoprotegerin/osteoclastogenesis inhibitory factor decreases human prostate cancer burden in human adult bone implanted into nonobese diabetic/severe combined immunodeficient mice.
    Yonou H, Kanomata N, Goya M, Kamijo T, Yokose T, Hasebe T, Nagai K, Hatano T, Ogawa Y, Ochiai A.
    Cancer Res; 2003 May 01; 63(9):2096-102. PubMed ID: 12727825
    [Abstract] [Full Text] [Related]

  • 4. Osteoprotegerin in prostate cancer bone metastasis.
    Corey E, Brown LG, Kiefer JA, Quinn JE, Pitts TE, Blair JM, Vessella RL.
    Cancer Res; 2005 Mar 01; 65(5):1710-8. PubMed ID: 15753366
    [Abstract] [Full Text] [Related]

  • 5. Prostate cancer cells-osteoblast interaction shifts expression of growth/survival-related genes in prostate cancer and reduces expression of osteoprotegerin in osteoblasts.
    Fizazi K, Yang J, Peleg S, Sikes CR, Kreimann EL, Daliani D, Olive M, Raymond KA, Janus TJ, Logothetis CJ, Karsenty G, Navone NM.
    Clin Cancer Res; 2003 Jul 01; 9(7):2587-97. PubMed ID: 12855635
    [Abstract] [Full Text] [Related]

  • 6. RANKL acts directly on RANK-expressing prostate tumor cells and mediates migration and expression of tumor metastasis genes.
    Armstrong AP, Miller RE, Jones JC, Zhang J, Keller ET, Dougall WC.
    Prostate; 2008 Jan 01; 68(1):92-104. PubMed ID: 18008334
    [Abstract] [Full Text] [Related]

  • 7. The effect of cyclooxygenase-2 (COX-2) inhibition on human prostate cancer induced osteoblastic and osteolytic lesions in bone.
    Gamradt SC, Feeley BT, Liu NQ, Roostaeian J, Lin YQ, Zhu LX, Sharma S, Dubinett SM, Lieberman JR.
    Anticancer Res; 2005 Jan 01; 25(1A):107-15. PubMed ID: 15816526
    [Abstract] [Full Text] [Related]

  • 8. Establishment and characterization of osseous prostate cancer models: intra-tibial injection of human prostate cancer cells.
    Corey E, Quinn JE, Bladou F, Brown LG, Roudier MP, Brown JM, Buhler KR, Vessella RL.
    Prostate; 2002 Jun 01; 52(1):20-33. PubMed ID: 11992617
    [Abstract] [Full Text] [Related]

  • 9. In vivo RANK signaling blockade using the receptor activator of NF-kappaB:Fc effectively prevents and ameliorates wear debris-induced osteolysis via osteoclast depletion without inhibiting osteogenesis.
    Childs LM, Paschalis EP, Xing L, Dougall WC, Anderson D, Boskey AL, Puzas JE, Rosier RN, O'Keefe RJ, Boyce BF, Schwarz EM.
    J Bone Miner Res; 2002 Feb 01; 17(2):192-9. PubMed ID: 11811549
    [Abstract] [Full Text] [Related]

  • 10. Influence of BMPs on the formation of osteoblastic lesions in metastatic prostate cancer.
    Feeley BT, Gamradt SC, Hsu WK, Liu N, Krenek L, Robbins P, Huard J, Lieberman JR.
    J Bone Miner Res; 2005 Dec 01; 20(12):2189-99. PubMed ID: 16294272
    [Abstract] [Full Text] [Related]

  • 11. Overexpression of noggin inhibits BMP-mediated growth of osteolytic prostate cancer lesions.
    Feeley BT, Krenek L, Liu N, Hsu WK, Gamradt SC, Schwarz EM, Huard J, Lieberman JR.
    Bone; 2006 Feb 01; 38(2):154-66. PubMed ID: 16126463
    [Abstract] [Full Text] [Related]

  • 12. Mixed metastatic lung cancer lesions in bone are inhibited by noggin overexpression and Rank:Fc administration.
    Feeley BT, Liu NQ, Conduah AH, Krenek L, Roth K, Dougall WC, Huard J, Dubinett S, Lieberman JR.
    J Bone Miner Res; 2006 Oct 01; 21(10):1571-80. PubMed ID: 16995812
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Comparison of Fc-osteoprotegerin and zoledronic acid activities suggests that zoledronic acid inhibits prostate cancer in bone by indirect mechanisms.
    Quinn JE, Brown LG, Zhang J, Keller ET, Vessella RL, Corey E.
    Prostate Cancer Prostatic Dis; 2005 Oct 01; 8(3):253-9. PubMed ID: 15999121
    [Abstract] [Full Text] [Related]

  • 15. Intraosseous growth of human prostate cancer in implanted adult human bone: relationship of prostate cancer cells to osteoclasts in osteoblastic metastatic lesions.
    Yonou H, Ochiai A, Goya M, Kanomata N, Hokama S, Morozumi M, Sugaya K, Hatano T, Ogawa Y.
    Prostate; 2004 Mar 01; 58(4):406-13. PubMed ID: 14968441
    [Abstract] [Full Text] [Related]

  • 16. Prostate-specific antigen induces apoptosis of osteoclast precursors: potential role in osteoblastic bone metastases of prostate cancer.
    Goya M, Ishii G, Miyamoto S, Hasebe T, Nagai K, Yonou H, Hatano T, Ogawa Y, Ochiai A.
    Prostate; 2006 Nov 01; 66(15):1573-84. PubMed ID: 16927388
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Prostate cancer bone metastases promote both osteolytic and osteoblastic activity.
    Keller ET, Brown J.
    J Cell Biochem; 2004 Mar 01; 91(4):718-29. PubMed ID: 14991763
    [Abstract] [Full Text] [Related]

  • 19. Differences in the cytokine profiles associated with prostate cancer cell induced osteoblastic and osteolytic lesions in bone.
    Lee Y, Schwarz E, Davies M, Jo M, Gates J, Wu J, Zhang X, Lieberman JR.
    J Orthop Res; 2003 Jan 01; 21(1):62-72. PubMed ID: 12507581
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.